Physician profile
Fadi Bashour
NPI 1821022708
$1,528.83
in general payments reported to CMS, 2019-2025
20 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $30.87 · 2021: $73.74 · 2022: $252 · 2023: $193 · 2024: $431 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.50 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.10 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Caldera Medical, INC | $146.73 | 2024 | Desara |
| Medtronic, INC. | $126.57 | 2022 | |
| Merck Sharp & Dohme LLC | $121.88 | 2019-2024 | Dificid |
| Sobi, INC | $99.40 | 2019 | |
| Janssen Biotech, INC. | $67.88 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $65.51 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.56 | 2023-2025 | Entyvio |
| Madrigal Pharmaceuticals | $37.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $35.38 | 2024 | Ibsrela |
| Amgen INC. | $24.20 | 2023 | Amjevita |
| Evoke Pharma, INC. | $23.95 | 2022 | |
| Qol Medical, LLC | $19.05 | 2024 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.92 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $17.14 | 2023 | Suflave, Sutab |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.59 | 2022 | |
| Gilead Sciences, INC. | $16.30 | 2025 | |
| Organon LLC | $15.34 | 2024 | |
| Ferring Pharmaceuticals INC. | $14.76 | 2023 | Rebyota |
| Celgene Corporation | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Bashour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.